News Screenpro Datametrex being a shareholder of Screenpro:
Add Biomedical Submits Application to USPTO for Rapid Breast Cancer Screening
2022-03-29 03:00 ET - News Release
Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") is pleased to announce that the Company's wholly owned subsidiary, Add Biomedical Inc. (Add Bio), is strengthening its library of intellectual property (IP). The Company has applied for the Cancer Antigen (CA) 15-3 rapid testing kit for breast cancer screening to the United States Patent and Trademark Office (USPTO).
Breast cancer is the world's most commonly occurring cancer. According to Cancer.ca, breast cancer is the second leading cause of cancer deaths in Canadian women. Recent reports show that 76 Canadian women are diagnosed with breast cancer everyday and on average, 15 of those women die from the disease everyday. (Source: Canadian Cancer Society)
The CA 15-3 screening test can detect early-stage breast cancer before it develops and therefore it can significantly reduce the lethal rate and risk to patients.
"In the midst of the ever-changing pandemic environment, we cannot ignore other infectious diseases that require early diagnosis screening. As we investigate IP testing kits for the North American marketplace, we are pleased to be starting our expansion with pursing the CA 15-3 breast cancer testing kit. We have helped the community navigate through this pandemic with Covid testing and look to do the same with breast cancer screening.", said Lena Kozovski, CEO of the Company.
"ScreenPro has been making strides in creating value for its shareholders with continued strength in Covid testing in the film and production industry as well as the company's recent diversification of product offerings. US patent applications and other opportunistic strategies are some of the ways that the company will continue to be innovative in protecting and growing value for our shareholders. We continue to build momentum and look forward to growing our shareholder value in 2022.", said Michael Yeung, Chairman of the Company.